A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects
Phase 2
Recruiting
- Conditions
- Cholestatic Liver InjuryDrug-Induced Liver InjuryMixed Liver Injury
- Interventions
- Drug: MT2004 CapsuleDrug: MT2004 Capsule Placebo
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Xi'An Aolitai Pharmaceutical Technology Co Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT06019936
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine,Renji Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath